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Introduction 
Sarcomas have been found in literature since the time of 
the ancient Egyptians in 1500 BC.1 Galen was the first to use 
the term “sarcoma” which comes from Sarx (flesh), and he 
distinguished them from cancers, that these arise in the 
flesh.2,3 Till the 1800s there was no progress and the 
mainstay of treatment was amputation. 
The first case series of bone tumours was published by 
Samuel Gross in 1879 after the advent of X-rays and 
microscope. He published 165 cases comrising of giant cell 
tumours, osteosarcoma and Ewing’s and he gave both 
clinical and pathological views.4 In 1900s James Ewing and 
Ernest Codman were the ones who formed the first 
orthopaedic tumour registry. Ernest Codman is known for 
what he called the Codman’s triangle.5,6 Ewing was a 
pathologist who suffered from chronic osteomyelitis, which 
was never cured.7 William Coley was a physician and is 
considered the pioneer of using radiation, immunotherapy 
and chemotherapy for cancers.8 He used Coley’s reagent, 
which was a bacterial solution, which he injected and 
found that the sarcoma regressed with that. His daughter 
formed an institute after that and the research of 
immunotherapy developed from there.8 
Over the last century, there has been a remarkable 
development in the study of bone and soft tissue sarcomas. 
This is primarily due to the improved knowledge of the 
nature of these lesions, improved imaging technology – 
previously it was just X-rays that were used to base the 
findings upon and skipped lesions as well as neurovascular 
status could not be identified. Hence a wide margin was 
not a plausible option. But now with improved imaging 
technology, such as magnetic resonance imaging (MRI), 
accurate knowledge of the extent of the tumour is 
possible.9,10 Biopsy techniques have also improved and 
there is better pathological recognition before starting the 
treatment.11 The most impact that has been made in 
survival has been the advent of chemotherapy because 
previously when there was only surgery available for bone 
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sarcomas, more than 80% patients used to die. The 5-year 
survival rate was <20%. But with the advent of 
chemotherapy, it has gone up to 78-80% and it has led to 
the increased survival in these patients and has helped in 
limb sparing surgery.12 The modern modular 
endoprosthesis has allowed the surgeons to salvage the 
limb even in large tumour resections. Allograft banks have 
also helped in reconstruction and limb-saving surgeries.13  
The current systematic review included studies from 2002 
to 2012 about the levels of evidence on which health 
professionals base decisions for surgical management of 
lower extremity bone tumours. PubMed, Education 
Resources Information Centre (ERIC), MEDLINE, EMBASE 
and Cochrane Review databases were searched and 
resulted in 63 articles that were thoroughly scanned. There 
were no Level I studies, 2(3.2%) Level II studies, 47(74.6%) 
Level III, and the remaining 14(22.2%) studies were Level IV 
and Level V. These included case reports, case series and 
experiences of different centres. It was evident that there 
are many protocols being used and all of them have been 
reported to have lots of advantages and disadvantages.14 
However, there is no set guideline and whatever has been 
developed has been on the basis of the experience of 
different centres and different surgeons. 
Soft Tissue Sarcoma: Soft tissue and bone sarcomas are very 
rare and heterogeneous group of tumours. They are <1% 
of all adult malignancies and <15% of all paediatric 
malignancies.15  
Risk factors include radiation therapy, especially in 
childhood, exposure to chemicals such as vinyl chloride 
which is used in the plastic industry and arsenic, 
immunodeficiency, prior injury and chronic tissue irritation 
such as burns and scars, Paget’s disease, bone infarcts, 
neurofibromatosis itself and various cancer syndromes like 
the hereditary retinoblastoma, Li Fraumeni syndrome and 
Gardner’s syndrome.16 
Sarcomas originate from mesoderm and are classified 
according to the adult tissue that they resemble. If they 
come from the muscle, they are rahbdomyo-sarcoma etc. 
and if they are bone sarcoma, they are classified according 
to the type of matrix they produce, like osteoid-producing 
ones are osteosarcomas and chondroid-producing are 
chondrosarcomas. With regard to grading, it is low, 
intermediate and high based on tumour morphology, 
extent of pleomorphism, atypia, mitosis and necrosis. Some 
use a 4-tier system as GI, II, III, IV but what needs to be 
understood is that the grade presents biological 
aggressiveness and correlates with the likelihood of 
metastasis. So a high-grade lesion has a higher chance of 
metastasising and it also has a high chance of being locally 
aggressive and progressing quickly with respect to time.17 
Usually sarcomas grow centrifugally and the periphery is 
usually the least mature and they are enclosed by a reactive 
zone, which is the pseudocapsule, and this consists of 
compressed tumour cells, fibro-vascular zone of reactive 
tissue and a variable inflammatory component. Sometimes 
there is local invasion of this capsule and there are “skip 
metastases” found locally. Sarcomas usually respect 
anatomical borders and they take the path of least 
resistance and grow within the anatomical compartment 
in which they arise. But later if the tumour is very 
aggressive, it can violate the walls. Yet joint involvement 
usually is rare.16,18 
Metastatic pattern usually involves dissemination almost 
exclusively through the blood. Lymphatic metastasis is 
negligible. Metastasis to lungs is the most common 
site.16,18,19 
Assessment of Patient: Age of the patient can be an 
extremely important determinant in some lesions in which 
the age range of occurrence may be quite narrow. For 
example, malignant osseous lesions in patients under one 
year of age are usually metastatic neuroblastoma.20 
Malignant osseous lesions in those aged 1-30 years are 
usually osteosarcoma or Ewing's sarcoma.16 Malignant 
osseous lesions in the 30-60-year range most commonly 
will be either chondrosarcoma, primary lymphoma or 
malignant fibrous histiocytoma, while malignant lesions in 
those aged >50 years most commonly will be due to 
metastatic disease or multiple myeloma.21,22  
Pain in bone sarcoma is initially activity-related and usually 
it becomes progressive and at rest or at night. Soft tissue 
sarcomas are usually painless and the patient presents with 
mass, except for nerve sheath tumours, which may come 
with pain and neurological signs.  
Physical examination should include general health, and, 
for the mass itself, the size, location, shape, consistency, 
mobility, tenderness, local temperature, change with 
position should be noted, and the same should be the case 
with atrophy of surrounding musculature, any neurological 
or vascular deficits, and systemic signs of other diseases like 
cafe-au-lait spots for neurofibromatosis. Also of importance 
is the examination of regional lymph nodes.17,23 
Radiological Assessment 
Plain X-ray: Initially, a musculoskeletal tumour should be 
simply imaged with a plain film that remains the most 
reliable imaging method for the assessment of both 
biological activity and probable histological diagnosis of 
an osseous lesion.10 Points to remember when assessing 
an X-ray include solitary/multiple lesions; location of the 
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bone involved; margins of the lesion well or ill-defined; the 
cortex eroded or destroyed; any peri-osteal new-bone 
formation; and the possibility of the tumour extending into 
the soft tissues. 
According to location and age, differential diagnosis for 
epiphyseal lesions usually within the age range 10-15 years 
are generally chondroblastoma,24 while in age range 30-40, 
they are usually giant cell tumours.25 Similarly, for 
diaphyseal lesions in the younger age group, it is Ewing’s 
sarcoma or fibrous dysplasia, and in the adults, it is usually 
lymphomas.21 For spine lesions in patients >40 years, 
metastasis and multiple myeloma are at the top of the list.26 
In young patients there are more benign tumours like 
histocytosis and haemangioma.27 
Patterns of bone destruction usually range from 
geographical to moth-eaten to permeative with increasing 
trend towards more aggressive tumours. Geographical 
lesions are probably locally invading tumours. Moth-eaten 
bone is found in myeloma and metastatic disease and 
signifies an increased disease burden.26 Permeative is 
locally aggressive and malignant tumour like Ewing’s and 
osteosarcoma.16 
Peri-osteal reactions are graded from solid in benign 
tumours with thicker peri-osteum to onion peel 
appearance representing aggressive lesion.27 Quickly 
growing tumour stretches the Sharpey’s fibres, those that 
attach the peri-osteum to the bone. They stretch to such a 
degree that they become perpendicular to the bone, and 
then, when ossification takes place, lead to sunburst time 
of appearance or speculated appearance. More malignant 
and aggressive tumours don’t have time for ossification, 
and results in a Codman’s triangle formation.5 This happens 
so quickly that the entire peri-osteum lifts up and it does 
not get time to ossify, and what one sees is a rim of the 
thing. So it is not a complete triangle.  
Then the matrix that the bone lays down, usually the 
cartilaginous tumours, results in a chrondroid matrix, which 
usually appears fluffy like popcorn. The osteoid matrix is 
more dense and the tumour usually remains inside the 
bone.28,29 
Computed Tomography (CT) Scan 
It is used for assessing ossification and integrity of cortex; 
pathological fractures; localising the nidus of osteoid 
osteoma; detecting whether a thin rim of reactive bone is 
around an ABC; evaluating calcification in a suspected 
cartilaginous lesion and endosteal cortical erosion in a 
suspected chondrosarcoma; surgical planning and custom-
made implant manufacturing; and pulmonary metastasis. 
 
A CT scan is the only tool if the MRI is prohibited. 
MRI: It has revolutionised bone sarcoma treatment. 
Benefits include calculation of the size and extent, 
intramedullary and extra-medullary spread and 
neurovascular structures, and it helps in a diagnosis, lipoma 
and haemangioma, without biopsy. Any soft tissue 
neoplasm deep to the fascia or >5cm is malignant until 
proven otherwise.10,30 
Bone Scan: A bone scan is helpful in determining multiple 
lesions or skeletal metastases with limited sensitivity and 
specificity. It would miss intramedullary small skip lesions 
and it may be false negative (FN) in multiple myeloma and 
some cases of renal cell carcinoma. 
Positron emission tomography (PET) Scan: The PET scan 
is the latest talk of the town.31 It checks the distribution of 
positron-emitting radioisotopes, which are linked to 
biologically active molecules. The fluorodeoxyglucose 
(FDG) used is an analogue of glucose that becomes 
trapped in malignant cells and in proportion to their 
respective rate of glycolysis/activity. This results in 
providing a non-invasive three-dimensional (3D) 
visualisation of anatomy, if combined with CT/MRI, as well 
as a quantitative assessment of the physiology of the 
tumour. Another area of help is to differentiate between 
post-surgical or post-radiation changes and recurrence of 
tumour, which the MRI cannot. Viable tumour cells will 
actively light up in a PET scan.  
Blood Tests: Albumin and total lymphocyte count (TLC) 
are used for assessing nutritional status of the patient 
which is directly associated with wound healing and 
wound dehiscence risk. Complete blood count (CBC) is the 
baseline to rule out infection and to check if leukaemia is 
suspected. Erythrocyte sedimentation rate (ESR) is elevated 
in infections, metastatic carcinoma and other tumours as 
well. If multiple myeloma is suspected, then the options are 
serum protein electrophoresis, prostate-specific antigen 
(PSA) for prostate carcinoma, calcium, alkaline phosphatase 
and parathyroid hormone (PTH) for metastatic or metabolic 
bone disease, and blood urea nitrogen (BUN) and 
creatinine if renal tumours are suspected. All the 
investigations should be completed before a biopsy. The 
differential diagnosis, extent of the lesion and potential 
resectability can affect the type of biopsy.32 
Biopsy: Fine needle aspiration cytology (FNAC) is very cost-
effective and can be done using a simple 10cc needle. It is 
up to 90% accurate at determining malignancy. It has fewer 
complications and may be good for obese patients or for 
tumours near neurovascular structure – if it is done 
radiologically-guided. The disadvantages are that it has 
very small sample size and requires a very expert and 
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dedicated pathologist, and one can only do cytology. It is 
good for metastatic lesions and sampling lymph nodes 
because you just need to identify if the lesion is malignant. 
Core needle biopsy gets a little tissue and is also cost-
effective. Core needle biopsy has a yield of up to 84-98% 
and accuracy of 81%. Accuracy further improves if it is done 
with image guidance.33  
Incisional biopsy is the gold standard. It can employ frozen 
section to confirm that adequate tissue is sent. Even for 
some tumours one can plan surgery in one go. If clinically 
a giant cell tumour is suspected, a frozen section is sent to 
get confirmation and to do the surgery at the same stage. 
Contamination can occur which can compromise definite 
resection, especially if done by an inexperienced surgeon 
in the field of orthopaedic oncology. Cost is another issue. 
To overcome that, studies reported that out-patient clinic-
based biopsy is safe, with diagnostic accuracy of 95.5% with 
low morbidity.34,35 
Excisional biopsy is for small subcutaneous masses <3cm 
which are unlikely to be malignant upon radiological 
examination. For larger deeper lesions, excisional biopsy is 
safe if the MRI appearance is diagnostic and confirmatory 
of lipomas.36 
Biopsy principles: The smallest of longitudinal incisions is 
needed. When doing a deep incision, like piercing the 
fascia, it should go through a single muscle compartment 
and should not contaminate an inter-muscular plane.37 
Demarcation lines and the principle of biopsy can be seen 
on the figure (figure).  
A knife or curette is used while ensuring it is sharp. If going 
for bone holes, they should be oblong so that one can 
increase the length of the bone hole, but should not 
increase its diameter, as diameter affects stability. The 
corners are kept round to avoid stress points.  
One should always obtain enough tissue and frozen section 
should be sent. If a tourniquet is used, it should not 
exsanguinate the limb. Any haematoma should be drained 
and haemostasis secured because the haematoma will be 
considered contaminated. Drains are used only when 
necessary. Drain tract is treated just like biopsy tract and 
has to be excised with it, and, as such, it should be in line 
with the incision.38,39 It is critical that biopsy should 
preferably be done by the primary oncology surgeon who 
will do the definite procedure, otherwise limb-saving 
results will be suboptimal. Just getting the diagnosis is not 
the key.  
Staging of Musculoskeletal Tumour: The Enneking 
staging system is the one that is accepted by the 
Musculoskeletal Tumour Society.40 This defines benign 
tumours into latent, active and aggressive. Latent tumours 
are the ones that remain static or heal spontaneously such 
as lipomas or non-ossifying fibromas. Active tumours are 
those that progress with growth, but are limited by natural 
barriers as they don’t grow out of the bone. Examples are 
angiolipoma and aneurysmal bone cyst. The aggressive 
tumours are the one ones that are progressive by growth, 
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Figure: 14-year-old boy with osteosarcoma over right buttock region, biopsied with large transverse incision. Clinical photograph with the patient in left lateral position, showing a 
large transverse incision (14 cm) just above the right buttock region done for an incisional biopsy for a suspected sarcoma (A). Right photograph showing the large incision 
(arrow) we were forced to do to include the previous large scar as well, which compromised the blood supply to the skin flap leading to marginal necrosis and second 
debridement and excision of necrotic skin. 
Asterisks showing L4 & L5 vertebrae levels..
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invasive and not limited by natural barriers, like the giant 
cell tumour or aggressive fibromatosis.  
Enneking staging of malignant tumours is based on 
histological grade, low or high, location, intra-
compartmental or extra-compartmental, and whether 
metastasis is present. It includes stage-I tumours, intra and 
extra-compartmental with no metastasis.40 
Similarly, the American Joint Committee on Cancer Staging 
system is the standard tumour, node and metastases (TNM) 
classification that covers all types of tumours. For soft tissue 
sarcomas, the T1 and T2 are according to the cut-off of 5cm. 
For the bone tumours, the T1 and T2  cut-off is 8cm.38,41 
Conclusion 
Bone and soft tissue sarcomas are frequently occurring 
neoplastic conditions which are present in all age groups, 
but commonly affect young population. Most are 
asymptomatic, but can present with pain or pathological 
fracture. These lesions are commonly diagnosed with plain 
radiographs. CT scan and MRI may be used to delineate 
anatomy and the extent of soft tissue involvement. 
Following the clinical, laboratory and radiological work-up, 
biopsy is the major mode of assessment to identify and 
lead to a definitive diagnosis. Based on the results, a 
directed approach is followed by a treatment plan which is 
surgery in most cases, and the decision is made with regard 
to the type of surgery to be planned. 
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